TUB Financière de Tubize SA

EBR · BE · Healthcare · Biotechnology · financiere-tubize.be

169.80EUR-2.64%Mkt Cap: 8.22B $P/E: 76.83Today

Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous sys…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap8.22B USD

Enterprise Value8.38B USD

Revenue (TTM)—

Gross Profit-3.22M USD

Net Income (TTM)101.33M USD

Revenue/Share—

Last Price169.80 EUR

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees—

CountryBE

SectorHealthcare

IndustryBiotechnology

ISINBE0003823409

Valuation

P/E (Trailing)76.83

P/E (Forward)—

PEG1.24

EV/EBITDA-2544.52

EV/Revenue—

P/S—

P/B3.91

EPS (TTM)2.21

EPS (Forward)—

52W Range

169.101% of range250.50

52W High250.50 EUR

52W Low169.10 EUR

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE4.94%

ROA4.82%

Growth

Revenue Growth—

Earnings Growth5.40%

Cash Flow & Leverage

Operating CF-3.30M USD

CapEx (TTM)—

FCF Margin—

FCF Yield-0.03%

Net Debt-54.24M USD

Net Debt/EBITDA16.46

Balance Sheet

Debt/Equity0.00

Current Ratio141.92

Quick Ratio141.92

Book Value/Sh44.62 EUR

Cash/Share1.12 EUR

Dividends

Fwd Div Rate1.08 EUR

Trail. Div Rate1.08 EUR

Div. Yield0.62%

5Y Avg Yield0.77%

Payout Ratio48.85%

Ex-Div DateMay 7, 2026

Pay Date—

Splits

Last Split2:1

Split DateJun 17, 2005

Analyst Consensus

Rating—

Target (Mean)286.00 EUR

Upside (mean)+68.4%

Target Range286.00 EUR – 286.00 EUR

# Analysts1

Ownership

Shares Out.44.51M

Float20.71M

Insiders53.49%

Institutions8.72%

Technical

SMA 50185.13 (-8.3%)

SMA 200209.79 (-19.1%)

Beta0.38

S&P 52W Chg14.58%

Avg Vol (30d)17.50K

Avg Vol (10d)15.67K

Technical Indicators

RSI (14)39.3

MACD-3.2135

MACD Signal-3.3053

MACD Hist.+0.0919

BB Upper181.92 EUR

BB Middle177.06 EUR

BB Lower172.20 EUR

BB Width5.49%

ATR (14)4.508 EUR

Vol Ratio (20d)1.34x